WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the MANDARA Phase III trial showed AstraZeneca’s FASENRA (benralizumab) met the primary endpoint of the trial and demonstrated ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss Syndrome, is a rare autoimmune disorder characterized by necrotizing vasculitis of small-to medium-sized blood ...

Please provide your email address to receive an email when new articles are posted on . This patient population had “better outcomes” when receiving benralizumab with or without prednisolone vs.

Positive full results from the NATRON Phase III trial showed AstraZeneca’s FASENRA(benralizumab) demonstrated a statistically significant delay in the time to first worsening or flare in ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. FASENRA PEN contains the active ingredient benralizumab. FASENRA PEN ...